Cas:140373-17-7 2-Amino-2-(4-fluorophenyl)ethanol manufacturer & supplier

We serve Chemical Name:2-Amino-2-(4-fluorophenyl)ethanol CAS:140373-17-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

2-Amino-2-(4-fluorophenyl)ethanol

Chemical Name:2-Amino-2-(4-fluorophenyl)ethanol
CAS.NO:140373-17-7
Synonyms:(R,S)-2-amino-2-(4-fluorophenyl)ethanol;Benzeneethanol, β-amino-4-fluoro-;2-amino-2-(4-fluorophenyl)ethan-1-ol;2-Amino-2-(4-fluorophenyl)ethanol;b-Amino-4-fluorobenzeneethanol
Molecular Formula:C8H10FNO
Molecular Weight:155.169
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:287.4±25.0 °C at 760 mmHg
Density:1.2±0.1 g/cm3
Index of Refraction:1.549
PSA:46.25000
Exact Mass:155.074646
LogP:0.47

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like (R,S)-2-amino-2-(4-fluorophenyl)ethanol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,b-Amino-4-fluorobenzeneethanol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,b-Amino-4-fluorobenzeneethanol Use and application,(R,S)-2-amino-2-(4-fluorophenyl)ethanol technical grade,usp/ep/jp grade.


Related News: This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.? 2-Amino-2-(4-fluorophenyl)ethanol manufacturer This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.? 2-Amino-2-(4-fluorophenyl)ethanol supplier For both Black and white women, younger age and ER-negative breast cancer were risk factors in the genes most strongly associated with breast cancer, including BRCA1, BRCA2 and PALB2. 2-Amino-2-(4-fluorophenyl)ethanol vendor Australia’s ban followed an earlier move by the US Friday to deny entry to foreign nationals who have traveled in China in the last 14 days. 2-Amino-2-(4-fluorophenyl)ethanol factory In 2016, in order to promote the innovative development, transformation and upgrading of the pharmaceutical industry, the Development and Reform Commission led the compilation of the Guiding Opinions on Promoting the Healthy Development of the Pharmaceutical Industry, which put forward requirements for all aspects of the medical industry and specifically proposed support for the field of chemical raw materials. .